CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Investigated for use/treatment in hepatitis (viral, C) and viral infection.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.